BioSpace News Archive

Neurvati Neurosciences today announced the appointment of Dr. Deborah Dunsire as a new member and the new chair of the company’s board of directors.

Vivasure Medical today announced it has treated the first large bore venous patient with the PerQseal ® Elite vascular closure system, a sutureless and fully bioresorbable large-bore vessel closure device.

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today announced that it has called an extraordinary general meeting of its shareholders (the “Extraordinary General Meeting”), to be held on May 22, 2024, at 10:00 a.m., Israel time.

RenovoRx, Inc. today announced the closing of its previously announced private placement of approximately $11.1 million in gross proceeds.

NovelMed today announced that the Food and Drug Administration (FDA) has awarded Orphan Drug Designation (ODD) to NM5072, an Alternative Pathway (AP) blocker anti-Properdin antibody, for the treatment of patients with Paroxysmal Nocturnal Hemoglobinuria (PNH).

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, “NRx”, the “Company”), a clinical-stage biopharmaceutical company, today announced that the Company has developed a novel, proprietary formulation of IV Ketamine for use as HTX-100.

IO Biotech today announced that Marjan Shamsaei, PharmD, joined the company as SVP, Commercial Development and Portfolio Lead for IO102-IO103, the company’s lead cancer vaccine candidate currently in a pivotal Phase 3 trial.

EarlyDiagnostics is pleased to announce that Co-CEO Gregory C. Critchfield, M.D. M.S., has received the State of Utah’s Governor’s Medal for his numerous science and technology contributions in industry.

Actinogen Medical Limited announces that the first patient has been randomized and treated in the XanaMIA phase 2b clinical trial in patients with biomarker-positive mild to moderate Alzheimer’s disease (AD).

TransCode Therapeutics, Inc. announced today that the U.S. Food and Drug Administration (FDA) has completed its review of the company’s Investigational New Drug (IND) application and concluded that the company may proceed with its Phase 1/2 multicenter, open-label, dose-escalation and dose-expansion study of its lead therapeutic candidate.